Late last week, Reuters reported that Johnson & Johnson was negotiating a deal to acquire Swiss biotech Actelion Ltd that would separate its commercialized portfolio from its R&D division, according to unnamed sources.
This could allow J&J to acquire Actelion with a cash offer of about $260 per share, which is a little more than it had offered earlier this month. It also would allow Actelion shareholders to benefit financially from Actelion's R&D pipeline, the story said. In addition, sources say the deal being discussed might involve Actelion's R&D pipeline to be placed in a new publicly traded company.
Read the Reuters article